1. Home
  2. CCIA vs CMMB Comparison

CCIA vs CMMB Comparison

Compare CCIA & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CCIA
  • CMMB
  • Stock Information
  • Founded
  • CCIA N/A
  • CMMB 2004
  • Country
  • CCIA
  • CMMB Israel
  • Employees
  • CCIA N/A
  • CMMB N/A
  • Industry
  • CCIA
  • CMMB Biotechnology: Pharmaceutical Preparations
  • Sector
  • CCIA
  • CMMB Health Care
  • Exchange
  • CCIA Nasdaq
  • CMMB Nasdaq
  • Market Cap
  • CCIA N/A
  • CMMB 37.3M
  • IPO Year
  • CCIA 2023
  • CMMB N/A
  • Fundamental
  • Price
  • CCIA $26.04
  • CMMB $1.89
  • Analyst Decision
  • CCIA
  • CMMB Strong Buy
  • Analyst Count
  • CCIA 0
  • CMMB 2
  • Target Price
  • CCIA N/A
  • CMMB $7.50
  • AVG Volume (30 Days)
  • CCIA N/A
  • CMMB 76.3K
  • Earning Date
  • CCIA N/A
  • CMMB 03-06-2025
  • Dividend Yield
  • CCIA N/A
  • CMMB N/A
  • EPS Growth
  • CCIA N/A
  • CMMB N/A
  • EPS
  • CCIA N/A
  • CMMB N/A
  • Revenue
  • CCIA N/A
  • CMMB N/A
  • Revenue This Year
  • CCIA N/A
  • CMMB N/A
  • Revenue Next Year
  • CCIA N/A
  • CMMB N/A
  • P/E Ratio
  • CCIA N/A
  • CMMB N/A
  • Revenue Growth
  • CCIA N/A
  • CMMB N/A
  • 52 Week Low
  • CCIA N/A
  • CMMB $0.55
  • 52 Week High
  • CCIA N/A
  • CMMB $2.55
  • Technical
  • Relative Strength Index (RSI)
  • CCIA 42.67
  • CMMB 40.27
  • Support Level
  • CCIA $26.14
  • CMMB $1.86
  • Resistance Level
  • CCIA $26.21
  • CMMB $2.05
  • Average True Range (ATR)
  • CCIA 0.11
  • CMMB 0.14
  • MACD
  • CCIA -0.06
  • CMMB -0.03
  • Stochastic Oscillator
  • CCIA 2.08
  • CMMB 7.42

About CCIA Carlyle Credit Income Fund 8.75% Series A Preferred Shares due 2028

Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.

Share on Social Networks: